Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
Abstract Non-small cell lung cancer (NSCLC) has limited treatment options. Expression of the RNA-binding protein (RBP) Musashi-2 (MSI2) is elevated in a subset of non-small cell lung cancer (NSCLC) tumors upon progression, and drives NSCLC metastasis. We evaluated the mechanism of MSI2 action in NSC...
Main Authors: | Petr Makhov, Igor Bychkov, Bulat Faezov, Alexander Deneka, Alexander Kudinov, Emmanuelle Nicolas, Rohan Brebion, Eleanor Avril, Kathy Q. Cai, Leonid V. Kharin, Mark Voloshin, Elena Frantsiyants, Nikolay Karnaukhov, Oleg I. Kit, Iuliia Topchu, Rushaniya Fazliyeva, Anna S. Nikonova, Ilya G. Serebriiskii, Hossein Borghaei, Martin Edelman, Essel Dulaimi, Erica A. Golemis, Yanis Boumber |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Oncogenesis |
Online Access: | https://doi.org/10.1038/s41389-021-00317-y |
Similar Items
-
Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression.
by: Leonid Kharin, et al.
Published: (2021-01-01) -
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
by: Karam Khaddour, et al.
Published: (2021-06-01) -
Opposing effects of inhibitors of Aurora-A and EGFR in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Anna S Nikonova, et al.
Published: (2015-10-01) -
Case report: reinitiating pembrolizumab treatment after small bowel perforation
by: Tim N. Beck, et al.
Published: (2019-04-01) -
EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
by: Anbang Wang, et al.
Published: (2020-01-01)